Biosimilars adoption in the US has taken around a decade longer than in Europe. The first biosimilar product - Sandoz's Zarxio - was only launched in September 2015, and the first monoclonal antibody 'second wave' biosimilar products were given the US Food and Drug Administration (FDA) thumbs up the following year. So in 2017, regulators and biosimilar developers have been playing catch-up with a wealth of guidance, approvals and even another biosimilar hitting the market.
See how the year panned out in our timeline below, and we'll promise to bring you all the latest 2018 biosimilar news and views in the new year. Thanks for reading!